Skip to content

US · XGN · MEDICAL - DIAGNOSTICS & RESEARCH

Exagen Inc. (XGN) intrinsic value and stock valuation

$3.61as of 2026-11-21 · Mkt cap 160.66M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Exagen Inc. DCF and intrinsic value

InvestorsCraft values XGN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from XGN’s statements →

Exagen Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Vista, CA 92081 exagen.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$66.6M+9.7% 5y CAGRd
20122025
Net income
-$-19.95M
20122025
Free cash flow
-$-14.27M
20122025
Total equity
$17.5M-16% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$66.6M$55.6M$52.6M$45.6M$48.3M
Operating income-$-14.07M-$-13.64M-$-22.84M-$-46.05M-$-24.07M
Net income-$-19.95M-$-15.12M-$-23.69M-$-47.39M-$-26.85M
EPSd-$-925.32K-$-830.77K-$-1.34M-$-2.77M-$-1.68M
Operating cash flow-$-13.62M-$-13.28M-$-14.46M-$-32.14M-$-20.27M
Capital expenditure-$-640K-$-520K-$-830K-$-4.32M-$-2.37M
Free cash flow-$-14.27M-$-13.79M-$-15.29M-$-36.46M-$-22.64M
Total assets$58M$44.7M$56.9M$86.2M$123.4M
Total debt$25.7M$23.2M$23.2M$35.2M$28.1M
Net debt-$-6.51M$1.17M-$-13.26M-$-27.19M-$-71.38M
Total equity$17.5M$9.54M$22.7M$42.5M$84.9M
Cash and short-term investments$32.2M$22M$36.5M$62.4M$99.4M
Income statement
20252024202320222021
Revenue$66.6M$55.6M$52.6M$45.6M$48.3M
Cost of revenue$27.8M$22.5M$23.1M$24.2M$20.6M
Gross profit$38.8M$33.1M$29.5M$21.4M$27.7M
Research and development expenses$6.25M$5.38M$4.87M$9.88M$7.24M
Selling, general and administrative expenses$46.6M$41.4M$47.4M$52M$44.5M
Other expenses$0.00$0.00$0.00$5.51M$0.00
Operating expenses$52.9M$46.8M$52.3M$67.4M$51.8M
Cost and expenses$80.6M$69.3M$75.4M$91.6M$72.4M
Interest income$290K$770K$1.52M$830K$20K
Interest expense$4.32M$2.23M$2.33M$2.45M$2.62M
Depreciation and amortization$2.12M$1.72M$2.17M$1.56M$950K
Ebitda-$-13.46M-$-11.14M-$-19.15M-$-43.66M-$-23.1M
Operating income-$-14.07M-$-13.64M-$-22.84M-$-46.05M-$-24.07M
Total other income/expenses, net-$-5.83M-$-1.47M-$-820K-$-1.62M-$-2.61M
Income before tax-$-19.9M-$-15.1M-$-23.66M-$-47.67M-$-26.68M
Income tax expense$50K$10K$30K-$-280K$170K
Net income-$-19.95M-$-15.12M-$-23.69M-$-47.39M-$-26.85M
Weighted average shares outstanding$21.6M$18.2M$17.7M$17.1M$16M
Weighted average diluted shares outstanding$21.6M$18.2M$17.7M$17.1M$16M
Balance sheet
20252024202320222021
Cash and short-term investments$32.2M$22M$36.5M$62.4M$99.4M
Net receivables$10.9M$7.83M$6.55M$6.08M$9.65M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$48.9M$36.5M$47.8M$72.6M$112.7M
Property, plant and equipment, net$8.37M$7.68M$8.49M$13.1M$4.77M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$5.51M
Long-term investments$200K$0.00$0.00$0.00$0.00
Total non-current assets$9.13M$8.23M$9.1M$13.6M$10.7M
Total assets$58M$44.7M$56.9M$86.2M$123.4M
Accounts payable$4.15M$4.14M$3.13M$3.05M$2.49M
Short-term debt$3M$1.72M$1.24M$1.93M$590K
Deferred revenue$680K$730K$0.00$0.00$0.00
Total current liabilities$14.2M$13.5M$11.9M$9.62M$9.32M
Long-term debt$22.7M$21.5M$22M$33.3M$27.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$26.4M$21.6M$22.4M$34.1M$29.2M
Capital lease obligations$2.8M$2.96M$3.74M$6.23M$0.00
Total liabilities$40.6M$35.2M$34.3M$43.8M$38.5M
Common stock$20K$20K$20K$20K$20K
Retained earnings-$-314.28M-$-294.33M-$-279.22M-$-255.53M-$-208.14M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$17.5M$9.54M$22.7M$42.5M$84.9M
Total investments$200K$0.00$0.00$0.00$0.00
Total debt$25.7M$23.2M$23.2M$35.2M$28.1M
Net debt-$-6.51M$1.17M-$-13.26M-$-27.19M-$-71.38M
Cash flow statement
20252024202320222021
Net income-$-19.95M-$-15.12M-$-23.69M-$-47.39M-$-26.85M
Depreciation and amortization$2.12M$1.72M$2.17M$1.56M$950K
Stock-based compensation$2.16M$1.76M$3.62M$4.7M$4.73M
Change in working capital-$-1.98M-$-3.08M$330K$1.67M-$-60K
Accounts receivable-$-3.02M-$-1.28M-$-470K$3.58M-$-740K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$40K$310K$70K$900K-$-660K
Net cash provided by operating activities-$-13.62M-$-13.28M-$-14.46M-$-32.14M-$-20.27M
Investments in property, plant and equipment-$-640K-$-520K-$-830K-$-4.32M-$-2.37M
Acquisitions, net$10K$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-630K-$-520K-$-800K-$-4.32M-$-2.42M
Common stock issued$22.4M$200K$310K$450K$69.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$24.4M-$-660K-$-10.63M-$-490K$64.7M
Net change in cash$10.2M-$-14.46M-$-25.9M-$-36.95M$42M
Cash at end of period$32.4M$22.2M$36.7M$62.6M$99.5M
Operating cash flow-$-13.62M-$-13.28M-$-14.46M-$-32.14M-$-20.27M
Capital expenditure-$-640K-$-520K-$-830K-$-4.32M-$-2.37M
Free cash flow-$-14.27M-$-13.79M-$-15.29M-$-36.46M-$-22.64M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Exagen Inc.

        Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.

        CEO
        John Aballi
        Employees
        216
        Beta
        2.02

        Explore

        Frequently asked questions

        What is the intrinsic value of Exagen Inc. (XGN)?

        Exagen Inc. (XGN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is XGN undervalued?

        XGN trades at a price of $3.61 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.